Inter-rater and intra-rater agreement of [^99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors, including those against programmed cell death protein-1 (PD-1) or its ligand (PD-L1), are routinely used to treat non-small cell lung cancer (NSCLC). PD-L1 is a validated prognostic and predictive immunohistochemical biomarker of anti-PD-1/PD-L1 therapy but displays temporospatial heterogeneity of expression. Non-invasive radiopharmaceutical techniques, including technetium-99m [^99mTc]-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT, have the potential to improve the predictive value of PD-L1 assessment. This study aims to determine the inter- and intra-rater agreement of the quantitative measurement of [^99mTc]NM-01 SPECT/CT in NSCLC.

Methods

Participants (n = 14) with untreated advanced NSCLC underwe

SUBMITTER: Hughes DJ 

PROVIDER: S-EPMC10232393 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature